Clinical trial · Interventional
Plasma Extracellular Vesicles in Meningioma Patients
Plasma Extracellular Vesicles in Meningioma Patients Following Radiotherapy as Liquid Biopsy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Explorative biomarker study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy
- description
- Explorative biomarker study
- interventionNames
- Other: Explorative biomarker study
Primary outcomes (1)
- measure
- dynamic of plasma EVs
- timeFrame
- until 2 years follwoing radiotherapy
- description
- Change of amount of plasma EVs in meningioma patients compared to sample taken before radiotherapy
Secondary outcomes (2)
- measure
- progession-fee survival
- timeFrame
- until 2 years follwoing radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * confirmed meningioma (histologically or MRI/DOTATOC-PET CT) * macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse) * indication for radiotherapy * completed wound healing after surgical intervention) * Alter ≥ 18 Jahre * Karnofsky Performance Score ≥ 60% * written informed consent * ability of subject to understand character and individual consequences of the trial * adequate contraception for women of childbearing potential Exclusion Criteria: * previous or known tumor diseases \< 5 years ago * previous (cerebral) radiotherapy * simultaneous chemo/immunotherapy * evidence that the patient cannot adhere to the study protocol (e.g., non-compliance) * the refusal of patients to participate in the study * participation in another clinical study or observation period in a competing trial
References
Publications (0)
Data not yet available